Table 4 Patient characteristics by EPPK1 expression levels in LUSC
From: Elucidating the role of EPPK1 in lung adenocarcinoma development
Characteristic | N | All LUSC1 (N = 140) | EPPK1 Low1 (N = 68) | EPPK1 High1 (N = 72) | P value2 |
|---|---|---|---|---|---|
Age | 139 | 66 (60–72) | 66 (60–73) | 64.5 (59.75–70) | 0.26 |
Gender | 139 | 0.66 | |||
Female | 35 (25.2%) | 18 (26.9%) | 17 (23.6%) | ||
Male | 104 (74.8%) | 49 (73.1%) | 55 (76.4%) | ||
Smoking Status | 137 | 0.23 | |||
Ever | 135 (98.5%) | 64 (97.0%) | 71 (100.0%) | ||
Never | 2 (1.5%) | 2 (3.0%) | 0 (0.0%) | ||
Pack Year | 139 | 50 (40–72.5) | 40 (27.5–60) | 60 (40–80) | < 0.001 |
Performance Status | 72 | 0.47 | |||
0 | 24 (33.3%) | 12 (33.3%) | 12 (33.3%) | ||
1 | 21 (29.2%) | 8 (22.2%) | 13 (36.1%) | ||
2 | 8 (11.1%) | 6 (16.7%) | 2 (5.6%) | ||
3 | 12 (16.7%) | 7 (19.4%) | 5 (13.9%) | ||
4 | 7 (9.7%) | 3 (8.3%) | 4 (11.1%) | ||
Stage | 140 | 0.43 | |||
I | 29 (20.7%) | 13 (19.1%) | 16 (22.2%) | ||
II | 12 (8.6%) | 4 (5.9%) | 8 (11.1%) | ||
III | 65 (46.4%) | 36 (52.9%) | 29 (40.3%) | ||
IV | 34 (24.3%) | 15 (22.1%) | 19 (26.4%) | ||
COPD | 97 | 54 (55.7%) | 25 (53.2%) | 29 (58.0%) | 0.63 |